Is a Risk Factor for Early Mortality

Slides:



Advertisements
Similar presentations
Facon T et al. Proc ASH 2013;Abstract 2.
Advertisements

April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
A Retrospective Study of Outcomes in Pediatric Hematology/Oncology Patients Receiving Continuous Venovenous Hemodialysis Y Avent 1, N Henderson 1, T Collie.
Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1.
Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
Transplant Creations1 Treatment & Transplant Program to improve disease outcome Transplant Creations Marlies Van Hoef.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths
Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Clinical Infectious Diseases 2012;55(6):764–70 Jan Vydra,1 Ryan M. Shanley,2 Ige George,1 Celalettin Ustun,1 Angela R. Smith,4 Daniel J. Weisdorf,1 and.
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
Pavan Kumar Bhamidipati 1, John F. DiPersio 1, Keith Stockerl-Goldstein 1, Geoffrey L. Uy 1, Peter Westervelt 1, Feng Gao 2, Ravi Vij 1, Mark A. Schroeder.
G. Lucchini on behalf of the EBMT PDWP SCT in pediatric AML in 1CR: does the conditioning regimen matter? Scientific Day 12 th May, 2016 London.
VALDEZ ET AL CLINICAL INFECTIOUS DISEASES 2011;52(6):726–735 R2 Kim Dong Hyun Decreased Infection-Related Mortality & Improved Survival in Severe Aplastic.
Population-based study on the impact of familial form of Waldenström’s macroglobulinemia on overall survival Vilhjálmur Steingrímsson1, Sigrún Helga.
ALBUMIN IS AN EFFECT MODIFIER IN THE RELATIONSHIP BETWEEN ERYTHROPOIETIN STIMULATING AGENT AND MORTALITY IN HEMODIALYSIS PATIENTS. Satoshi Mikami1, Takayuki.
39th ESMO Congress Madrid, Spain – 30 September Poster 979P
Results from the intermountain heart collaborative study
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Retrospective analysis of conditioning regimen containing decitabine of allogeneic stem cell transplantation for myelodysplastic syndrome and myeloproliterative.
Copyright © 2012 American Medical Association. All rights reserved.
MedStar Washington Hospital Center Cardiac Catheterization Conference
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
at First Pavlov State Medical University of Saint-Petersburg, Russia
Department of Geriatrics Unit of Respiratory Pathophysiology
ASCT for AL Seok Jin Kim
Clinical outcome after SVR: Veterans Affairs
Utilizing the Candida Score to Identify Patients at Increased Risk for
Haploidentical Transplantation with Post-transplant Cyclophosphamide and Melphalan-based Conditioning– A retrospective Analysis of the First 100 Patients.
Supplemental table 1 Patients' characteristics Variables Number
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation
Shahad Abbas1,2 Alison H Thomson1,2 B) non-malignant patients.
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung
M. Bregni, M. Bernardi, P. Servida,
EBMT Activity Survey Teams Patients Transplants
Fluid Accumulation During The Early Phases Of Hematopoietic Stem Cell Transplantation (HSCT) Is Associated With An Increased Risk Of Mortality and Complications.
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
Il trapianto allogenico da donatore alternativo dopo condizionamento a ridotta intensità Alessandro Rambaldi.
Whom should you refer for allogeneic stem cell transplantation?
PREDICTIVE FACTORS AFFECTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION USING RIC REGIMENS: EXPERIENCE FROM A SINGLE CENTRE Dott.ssa M. Medeot.
The Prevalence of and Contributed Risk Factors of Cardiovascular Diseases among People with Spinal Cord Injury: A Retrospective Study Ramzi Alajam.
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase by Jiří Pavlů,
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Letermovir(Prevymis™) Guidelines for Inpatient Use
Hematopoietic Stem Cell Transplantation for Patients with AML
Impact of Platelet Reactivity Following Clopidogrel Administration
Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation,
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Mohamed L. Sorror, MD, MSc ASH Oral presentation December 2018
Clinical Lymphoma, Myeloma and Leukemia
Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients by Jenna Sopfe, Laura Pyle, Amy K.
Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova
Therapy-related acute myeloid leukaemia following treatment for cancer in childhood: a population-based registry study Introduction Acknowledge co-authors.
by Jan J. Cornelissen, and Didier Blaise
A suite of community-contributed programs to produce outcome tables and graphs for demographic and survival data Not theory-heavy, Stata-heavy or anything.
Presentation transcript:

Is a Risk Factor for Early Mortality Weight Gain in the First 10 Days after Hematopoietic Stem Cell Transplantation Is a Risk Factor for Early Mortality Lucila Nassif Kerbauy, Erika MM Costa, Juliano Cordova Vargas, Claudia Mac Donald Bley Nascimento, Joyce Esteves Hyppolito, Ricardo Helman, Alessandro de Moura Almeida, Jose Mauro Kutner, Juliana Folloni Fernandes, Andreza Alice Feitosa Ribeiro, Iracema Esteves, Eduardo Cerello Chapchap, Guilherme Fleury Perini, Paulo Vidal Campregher, Jairo Sobrinho, Claudio Galvão de Castro Junior, Breno Moreno Gusmão, Fabio R. Kerbauy, Nelson Hamerschlak and Fabio P S Santos A landmark analysis at D+100 revealed that the negative impact of weight gain by D+10 on survival was restricted to the first 100 days, as after this time point there was no survival difference between the two groups (HR 1.35; p=0.41; 95% CI 0.65-2.83).  Table 2 – Multivariate Cox Analysis Introduction: Hematopoietic stem cell transplantation (HSCT) is an effective treatment option for patients with hematological and neoplastic diseases. Despite recent improvements, HSCT is still associated with a significant risk of mortality. Determining risk factors for death within the first 100 days after HSCT could help to identify patients who would benefit from interventions in order to decrease that risk. We analyze the impact of weight gain on early (100-days) mortality in patients who underwent HSCT at our institution. Results: Variable Hazard Ratio P 95% Confiance Interval Gender (male vs female) 1.25 0.341 0.78 - 2.01 Other HSC sources vs Autologous Matched Related Donors 1.36 0.462 0.60 - 3.08 Matched Unrelated Donors 1.20 0.687 0.48 - 3.02 Mismatched related/unrelated donors 1.39 0.487 0.54 - 3.55 Cord blood units 2.75 0.020 1.17 - 6.45 Age 1.01 0.153 0.99 -1.02 Other Diagnosis vs acute leukemia or chronic myeloid disorders Lymphoma/multiple myeloma 0.39 0.014 0.18 - 0.82 Non-malignant hematological disorders 0.43 0.034 0.19 - 0.91 ≥6% BW gain 2.72 0.0001 1.65 - 4.48 The results of the ROC curve defined the cut-point of 6% weight gain by 10 days post-SCT as the best predictor for OS. Twenty-one percent of patients had a ≥6% gain in BW until the first 10 days post-HSCT. Table 1 – Baseline Features Feature (n=331) % Median age (range), years old 43 (<1-76) Male sex 60 Source of cells Autologous Cord blood Matched related donor Matched unrelated donor Cord blood Mismatched related/unrelated donors 46 16 12 10 Disease Acute leukemia or chronic myeloid neoplasias Lymphoma, multiple myeloma Non-malignant hematological disorders 34 42 24 Objectives: To determine the impact of weight gain during the first 10 days post-HSCT on 100 days mortality. Conclusions ≥6% BW gain by D+10 is a risk factor for early mortality in both autologous and allogeneic HSCT. The most common cause of death in these patients is infectious-related complications. An increase in BW is related to the development of an inflammatory state, probably induced by the conditioning regimen. BW gain is a simple variable that can be easily used to determine prognosis of patients post-allogeneic HSCT, and further studies are needed to determine its etiology. Material and Methods: We retrospectively reviewed the medical charts of 331 patients who underwent HSCT at our institution from January, 2007 until December, 2013. Weight gain definition: The highest body weight during conditioning regiment and 10 days post-SCT periods was used to calculate body weight increase in relation to baseline BW The primary endpoint was mortality within 100 days post HSCT. Overall survival (OS) was estimated from the time of HSCT until death, and surviving patients were censored at last follow-up. There was no difference in baseline levels of C-reactive protein (4.8 mg/L vs. 7.4, p=0.37), but by D+10 patients who gained more BW had higher CRP (116.7 mg/L vs. 178.6 mg/L; p=0.01). In a logistic regression analysis, a ≥6% BW gain by D10 was associated with an increased risk of being dead within 100 days (coefficient 1.75; p<0.0001; 95% CI 0.90-2.61). Among 18 patients who died within 100 days and had a ≥6% BW gain by D+10, causes of death included pneumonia (N=4), septic shock (N=9), fungal endocarditis (N=1), ischemic stroke (N=1) and disease progression (N=3). Contact Details Lucila N Kerbauy/Fabio PS Santos Department of Stem Cell Transplantation Hospital Israelita Albert Einstein 627 Albert Einstein Avenue Sao Paulo, SP – ZIP CODE: 05651-901 +55 (11) 97043-2223 santos.fabio2@einstein.br Disclosure There are no relevant conflicts of interest to disclose.